New Delhi: Pathology laboratory chain Metropolis Healthcare Limited has announced the launch of its Centre of Genomics, as it looks to expand its reach to support precision diagnostics. With this, the company aims to offer genomics testing at scale, as it deploys American biotech major Illumina’s NovaSeq ™X Series to scale genomics testing, besides offering 500 additional tests to support oncology, neurology, transplant immunology and rare disease diagnoses.
Though further details haven’t been revealed yet, Metropolis is aiming to first launch these labs in Mumbai and Delhi NCR, offering clinically actionable genomic insights. Given the increasing caseloads of cancer and complex genetic disorders in India, genomic testing is crucial for healthcare providers to offer a personalised diagnostic plan.
“Genomics marks a decisive inflection point for diagnostics in India, expanding the role of laboratories from disease detection to risk prediction, therapy personalisation, and long-term disease management. As genomics increasingly informs lifelong medical decisions, leadership in this space is defined not by adoption alone, but by rigorous validation, deep expertise, quality assurance, and clinical responsibility. Through the Centre of Genomics, we bring together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations. Supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms.” Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said in a press release.
“The Centre of Genomics has been designed to translate advanced genomic science into actionable clinical decision-making across high-impact disease areas, including oncology, reproductive health, neurology, transplant immunology, and rare diseases. Our differentiation lies in rigorous validation, multi-platform testing, and deep clinical integration, ensuring results are reliable and clinically meaningful. With over 220 validated genomic tests and a clear roadmap to expand beyond 500 assays over the next two to three years, the Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways.” Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, added.
